Eris Lifesciences Ltd. (ERIS): Eris Lifesciences Share Price near 52-week low after 2.65% drop
- September 29, 2026
- Posted by: Chaitanya Auti
- Category: News
Eris Lifesciences Share Price is under pressure today, with Eris Lifesciences Ltd. (ERIS) trading at Rs 1,203.20, down 2.65% from the previous close, and close to its 52-week low zone. The company’s market capitalisation stands at Rs 17,490.08 crore, keeping Eris Lifesciences Share Price in focus for investors tracking Eris Lifesciences Share Price Today and Eris Lifesciences Stock News.
The latest move confirms a near 52-week low event, but the supplied data does not establish a company-specific catalyst. What the data does show is a weak short-term price pattern, a decline below recent opening levels and a setup that keeps Eris Lifesciences Share Price relevant for technical analysis, fundamental analysis and sector comparison on Univest. In that context, the stock’s current move matters because it comes with an RSI below 40, a price below key moving averages and a valuation that needs to be read against the healthcare and pharmaceuticals peer set.
Eris Lifesciences Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,203.2 |
| Previous Close | Rs 1,236 |
| Today's Move | Rs -32.8 (-2.65%) |
| Open | Rs 1,229.75 |
| High | Rs 1,229.75 |
| Low | Rs 1,182.5 |
| Market Capitalisation | Rs 17,490.08 crore |
Eris Lifesciences Ltd. (ERIS) traded at Rs 1,203.2 versus the previous close of Rs 1,236, a fall of 2.65%. The stock opened at Rs 1,229.75, reached a high of Rs 1,229.75, touched a low of Rs 1,182.5.
Eris Lifesciences Share Price Today reflects a clear intraday setback. The stock opened at Rs 1,229.75, matched that as its day high, and then moved to a low of Rs 1,182.50 before ending at Rs 1,203.20. That leaves the share price below the previous close of Rs 1,236, with a decline of Rs 32.80 or 2.65%. For investors following Eris Lifesciences Share Price Live, the important point is that the stock is trading close to its 52-week low rather than showing a broad rebound.
Price action also matters because Eris Lifesciences Share Price is below its 50-day moving average of Rs 1,309.20 and its 200-day moving average of Rs 1,363.37. That positioning suggests the stock is still trading under medium-term and long-term reference levels. In stock market today screens, such a move often keeps the name among stocks in news and stocks at 52 week low, especially when broader share market today sentiment stays cautious. The next read-through comes from technical analysis and from whether the valuation and business metrics can justify renewed interest.
Eris Lifesciences Ltd. (ERIS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 17,490.08 crore |
| P/E Ratio | 26.63x |
| P/B Ratio | 4.25x |
| ROE | 19.23% |
| ROCE | 14.47% |
| EPS | Rs 46.41 |
| Book Value Per Share | Rs 290.65 |
| Dividend Yield | 0% |
Eris Lifesciences Ltd. (ERIS) fundamental metrics show P/E 26.63x, P/B 4.25x, ROE 19.23%, ROCE 14.47%. These figures provide context only and are not a buy or sell signal.
Eris Lifesciences Ltd. has a market capitalisation of Rs 17490.08 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 26.63x, P/B at 4.25x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 19.23% and ROCE of 14.47%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 46.41, book value per share of Rs 290.65, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 28.3x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 26.63x |
| Benchmark Median P/E | 28.3x |
| Benchmark Average P/E | 41.69x |
| Benchmark P/E Range | 0x to 707.31x |
| Company P/B Ratio | 4.25x |
| Benchmark Median P/B | 2.83x |
| Company ROE | 19.23% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 14.47% |
| Benchmark Median ROCE | 13.46% |
| Company Market Capitalisation | Rs 17,490.08 crore |
| Benchmark Median Market Cap | Rs 782.41 crore |
Eris Lifesciences Ltd. (ERIS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Eris Lifesciences Ltd. (ERIS) has a P/E ratio of 26.63x, which is below the benchmark median of 28.3x, a difference of -5.9%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Eris Lifesciences Ltd. (ERIS) has a ROE of 19.23%, which is above the benchmark median of 11.7%, a difference of +64.36%. Eris Lifesciences Ltd. (ERIS) has a ROCE of 14.47%, which is above the benchmark median of 13.46%, a difference of +7.5%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Suven Pharmaceuticals Ltd. | COHANCE | 17,563.13 | 163.48 | 4.51 | 4.02 | 6.12 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 17,109.18 | 47.83 | 2.36 | 5.97 | 8.69 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,975.19 | 24.21 | 2.87 | 12.35 | 11.74 |
| Pfizer Ltd. | PFIZER | 18,323.34 | 24.69 | 4.12 | 17.16 | 23.39 |
| ONESOURCE SPECL PHARMA L | ONESOURCE | 18,359.27 | 0 | 3.07 | -1.26 | 0.44 |
Eris Lifesciences Ltd. (ERIS) has a P/E ratio of 26.63x compared with the displayed peer median of 24.69x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 19.23% compares with a peer median of 5.97% across the companies shown in the table. ROCE stood at 14.47% versus the displayed peer median of 8.69%, providing a capital-efficiency comparison. Eris Lifesciences Ltd. (ERIS) has a market capitalisation of Rs 17,490.08 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Eris Lifesciences
- Eris Lifesciences Share Price is trading close to its 52-week low, keeping price action in focus.
- RSI at 33.07 shows weak momentum, so Eris Lifesciences Technical Analysis remains important.
- Valuation is below the industry median on P/E, but above the median on P/B.
- ROE of 19.23 and ROCE of 14.47 support the Eris Lifesciences Fundamental Analysis case.
- The stock is being tracked against healthcare peers, where profitability compares reasonably well.
About Eris Lifesciences
Eris Lifesciences Ltd. operates in the healthcare sector and the pharmaceuticals & drugs industry. The supplied data places the company in a large and established peer set, with 198 companies in the same industry benchmark and 285 companies in the wider sector comparison. That backdrop matters because pharma valuations often depend on the quality of earnings, return ratios and how the market reads growth consistency.
Recent financial figures show revenue of Rs 8,732.5 crore in June 2026 and net profit of Rs 1,423.9 crore in the same period. The company also reported EPS of 46.41 and book value per share of Rs 290.65, which helps frame the underlying earning power behind Eris Lifesciences Share Price. In simple terms, the business has enough scale and profitability to remain relevant even when the share price is under pressure, which is why Eris Lifesciences Share Price News continues to attract attention.
Track Eris Lifesciences Share Price on Univest
Use Eris Lifesciences Ltd. (ERIS) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Readers can track Eris Lifesciences Share Price on Univest for live price updates, technical indicators, fundamental ratios, sector comparison, peer context and 52-week levels. Univest also helps follow Eris Lifesciences Share Price Today, Eris Lifesciences Stock News and Eris Lifesciences Latest News in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
Why is Eris Lifesciences Share Price falling today?
Ans. The supplied data confirms a 2.65% decline in Eris Lifesciences Share Price, but it does not establish a company-specific catalyst. The move keeps the stock near its 52-week low and below key moving averages.
What is Eris Lifesciences Share Price today?
Ans. Eris Lifesciences Share Price today is Rs 1,203.20, after moving down Rs 32.80 from the previous close of Rs 1,236. The stock opened at Rs 1,229.75 and stayed under pressure through the session.
Is Eris Lifesciences near its 52-week low?
Ans. Yes, Eris Lifesciences Share Price is trading near its 52-week low zone. The data confirms a near-52-week-low event, which keeps investor focus on support levels, valuation and broader healthcare sector comparison.
How does Eris Lifesciences compare on valuation?
Ans. Eris Lifesciences Share Price trades at a P/E of 26.63 and a P/B of 4.25. That places it below the industry median on P/E, but slightly above the industry median on P/B.
What do Eris Lifesciences fundamentals show?
Ans. The company shows ROE of 19.23, ROCE of 14.47, EPS of 46.41 and book value of Rs 290.65. These figures suggest solid profitability and support the Eris Lifesciences Fundamental Analysis view.
How does Eris Lifesciences compare with peers?
Ans. Compared with peers such as Alembic Pharmaceuticals, Pfizer and Marksans Pharma, Eris Lifesciences Share Price sits near the middle on valuation and above several peers on ROE and ROCE, based on the supplied figures.
What should investors monitor next in Eris Lifesciences Share News?
Ans. Investors should monitor price action near support, any move back above moving averages, the next financial results and changes in shareholding data. Those factors will shape Eris Lifesciences Share News more than intraday noise.